Enrollment in the Zoster Eye Disease Study. Issue 12 (December 2020)

• Record Type: Journal Article
• Authors: Cohen, Elisabeth J.; Jeng, Bennie H.; Troxel, Andrea B.; Lee, Myeonggyun; Shakarov, Gabriel; Hochman, Judith; Gillespie, Colleen
• Is Part Of: Cornea. Volume 39:Issue 12(2020)
• Publication Date: 2020-12
• Subjects: enrollment barriers -- herpes zoster ophthalmicus -- antiviral therapy -- valacyclovir -- Zoster Eye Disease Study; Cornea -- Periodicals; Cornea -- Periodicals; Cornée -- Périodiques; 617.719
• DOI: 10.1097/ICO.0000000000002392
• Languages: English
• ISSNs: 0277-3740

Abstract

Abstract : Purpose: To present the results of a survey of the Zoster Eye Disease Study (ZEDS) investigators regarding barriers to the enrollment of study participants and approaches to overcome them. Methods: ZEDS is a multicenter randomized clinical trial supported by the National Eye Institute to determine whether prolonged suppressive valacyclovir reduces the complications of herpes zoster ophthalmicus (HZO), relative to placebo. Enrollment of study participants is currently far below expectations. An institutional review board–approved anonymous internet survey was conducted of ZEDS investigators to study their experiences and opinions regarding barriers to enrollment and various approaches to overcome them. Results: The overall survey response rate was 54% (79/145). Only 29% (23/79) agreed that it is easy to enroll study participants. Regarding patient barriers, 69% (55/79) agreed that HZO patients want to be treated with antiviral medication and 69% (54/78) agreed that HZO patients on antivirals do not want to be randomized. Regarding personal barriers facing investigators, 91% (72/79) agreed that antivirals are effective and 100% that the research questions ZEDS is designed to answer are very important. Fewer than 30% of respondents believed that steps taken to increase enrollment have been very helpful. Over half (54%, 42/78) believed that advertising on social media would be moderately or very effective. Conclusions: Belief among ZEDS investigators that antivirals are effective, and the preference of patients to be treated with antivirals rather than be randomized in ZEDS, are major barriers to enrollment. New approaches to overcoming barriers are necessary to develop an evidence-based standard of care for treatment of HZO. Abstract : Supplemental Digital Content is Available in the Text.